Clinical trials: Cancer Esophagus
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Esophageal Cancer, Gastro-esophageal Junction Cancer
Quality of Life With Esophageal Stent Trial
The aim of this study is to compare, specialist nurse home visits in patients with inoperable cancer in the esophagus or cardia, who are palliated with Self Expanding Metal Stent, to standard patient contact with regards to…
- Trial name
- QUEST (NCT01044511)
- Testing
- Home visits, standard
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Michael Bau Mortensen
Stomach Neoplasms, Esophageal Neoplasms
Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer
This phase II trial studies how well combination chemotherapy works in treating patients with advanced stomach, gastroesophageal, or esophageal cancer.
- Trial name
- FOLFIRINOX (NCT01928290)
- Testing
- Irinotecan, Trastuzumab, Oxaliplatin
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Washington University School of Medicine
Upper GI Cancer
Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
Regorafenib as a Second Line Single Agent in the Treatment of Metastatic or Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
- Trial name
- NCT02241720
- Testing
- regorafenib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Utah
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Neoplasm, Stomach, Neoplasm, Colorectal
Endoscopic Submucosal Dissection Registry
This is a patient registry for all cases of pre-neoplastic or early neoplastic digestive tract lesions treated with curative intention by endoscopic submucosal dissection (ESD) technique.
- Conditions
- Neoplasm, Stomach, Neoplasm, Colorectal, Neoplasm, Esophagus, Neoplasm, Duodenal
- Trial name
- ESDREG (NCT06033976)
- Testing
- Endoscopic submucosal dissection (ESD)
- Where
- Romania
- Volunteers
- 200 people
- Sponsor
- Carol Davila University of Medicine and Pharmacy
Advanced Colorectal Neoplasms, Throat Cancer
Fecal Screening Assay for Taiwanese Population
Fecal occult blood test (FOBT) is a convenient tool for the screening of asymptomatic gastrointestinal (GI) bleeding while 「guaiac-based fecal occult test (G-FOBT) 」 is increasingly replaced by the use of an 「immunochemical-based…
- Conditions
- Advanced Colorectal Neoplasms, Throat Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT01341197
- Testing
- Fecal immunochemical test, guaiac fecal occult-blood test, and Helicobacter pylori stool antigen test
- Where
- Taiwan
- Volunteers
- 3,172 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
This partially randomized phase I/II trial studies the side effects and best dose of c-Met inhibitor AMG 337 when given together with oxaliplatin, leucovorin calcium, and fluorouracil and to see how well they work in treating…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer
- Trial name
- NCT02344810
- Testing
- c-Met inhibitor AMG 337, oxaliplatin, leucovorin calcium
- Where
- United States
- Sponsor
- Eastern Cooperative Oncology Group
Anxiety Disorder, Worry
Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors
This randomized clinical trial studies a cognitive-behavioral intervention to treat worry, uncertainty, and insomnia in cancer survivors.
- Conditions
- Anxiety Disorder, Worry, Uncertainty, Sleep Disorders
- Trial name
- FOCUS (NCT01929720)
- Testing
- Cognitive-behavioral therapy for worry, uncertainty & insomnia
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Non-small Cell Lung Cancer, Esophageal Cancer
Radiation-induced Toxicity of the Heart
Late side effects in radio(chemo)therapy [R(CH)T] pose a critical limitation to patients' overall survival and quality of life. Even though toxicities of the heart are highly relevant for patients with cancer in the thoracic…
- Conditions
- Non-small Cell Lung Cancer, Esophageal Cancer, Breast Cancer Female
- Trial name
- CorTox (NCT06986291)
- Testing
- Imaging and biomarkers
- Where
- Germany
- Volunteers
- 325 people
- Sponsor
- Technische Universität Dresden
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Esophageal Cancer
S-1 Plus Nedaplatin With Concurrent Radiotherapy for Advanced Esophageal Cancer
Patients with advanced esophageal cancer will receive thoracic radiation therapy 60Gy over 30 fractions,and concurrent with s-1 and nedaplatin.
- Trial name
- NCT01175460
- Testing
- S-1, Nedaplatin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhejiang Cancer Hospital
Gastroesophageal Reflux Disease, Esophageal Cancer
Decision Aid for Gastroesophageal Reflux Disease Management
The study is to test a decision aid that is designed to help patients make decision regarding management of their gastroesophageal reflux disease (GERD).
- Conditions
- Gastroesophageal Reflux Disease, Esophageal Cancer, Barrett's Esophagus
- Trial name
- NCT01641887
- Testing
- Decision Aid
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Stomach Neoplasms
Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors
This is a multi-centre Phase 2 study. The study will evaluate the activity and safety of AMG 337 in patients who have MET amplified gastric, gastroesophageal junction or esophageal adenocarcinoma or other MET amplified solid…
- Trial name
- NCT02016534
- Testing
- AMG 337
- Where
- 97 sites in United States, Australia and 16 more
- Volunteers
- 60 people
- Sponsor
- Amgen
Barrett's Esophagus
Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus
The purpose of this study is to determine whether treatment with an experimental drug called YF476 in patients with Barrett's esophagus reduces the expression of tissue markers that are associated with an increased risk of…
- Trial name
- NCT01298999
- Testing
- YF476
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Columbia University
Gastric Cancer, Gastroesophageal-junction Cancer
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
This is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal…
- Conditions
- Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
- Trial name
- NCT05539430
- Testing
- LB1908
- Where
- 9 sites in United States
- Volunteers
- 56 people
- Sponsor
- Legend Biotech USA Inc
Subjects With Resectable and Localized Gastric Cancer, Subjects With Resectable Esophageal Cancer or Liver Cancer
Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers
This is a phase II, open-label, prospective single-centered study. Subjects who meet the inclusion/exclusion criteria will be allocated to appropriate cohorts: 1) gastric cancer, 2) esophageal cancer and 3) hepatocellular…
- Conditions
- Subjects With Resectable and Localized Gastric Cancer, Subjects With Resectable Esophageal Cancer or Liver Cancer, Subjects With Resectable Liver Cancer
- Trial name
- NeoChance (NCT04196465)
- Testing
- IMC-001
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Asan Medical Center
Esophagus Cancer
Clinical Study on Noninvasive Evaluation of Ivonescimab Antibody Distribution and Expression in Esophageal Cancer Patients by 89Zr-AK112 PET Imaging
As a humanized bispecific antibody targeting PD-1 and VEGF-A, everolizumab exhibits high specificity for binding PD-1 and VEGF-A in vivo.
- Trial name
- NCT07440212
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.